This Project is supported by funds from European Fund for regional development and the county of Brandenburg.

Manufacturer:
Pentracor GmbH
Neuendorfstraße 23 b/d
16761 Hennigsdorf
Germany
Tel.: +49 3302 20944935
Fax: +49 3302 20944999
info@pentracor.de
www.pentracor.de

Selective removal of C-Reactive Protein

Therapeutic options:

- Acute Myocardial Infarction
- Stroke
- Cerebral Ischemia
- Rheumatoid Diseases
- Inflammatory Bowel Disease
- Acute Pancreatitis
- SIRS (post-op)

Features:

- selective
- effective
- regenerable
- multi-use
- easy
- safe
C-reactive protein (CRP)

After an acute incident, e.g. myocardial infarction or stroke in most patients the level of the acute-phase-protein CRP is elevated dramatically.

Equally a lot of chronic diseases, e.g. Crohn’s disease, colitis ulcerosa or rheumatoid diseases are often associated with a permanently elevated CRP level.

CRP is widely known as an inflammatory marker. But there is substantial evidence that CRP plays a key role in tissue injury in the event of inflammation\(^1,2,3\).

CRP apheresis with PentraSorb\textsuperscript{®} CRP

The therapeutic CRP apheresis with PentraSorb\textsuperscript{®} CRP is a new therapeutic option for diseases where the reduction of CRP level may prevent further tissue damage.

The CRP apheresis is performed in a number of cycles in which CRP removal and adsorber regeneration alternate.

The safety and efficiency of CRP apheresis with PentraSorb\textsuperscript{®} CRP have been proven in pre-clinical\(^4\) and clinical studies.

Medical equipment

PentraSorb\textsuperscript{®} CRP is used for plasma perfusion in an extracorporeal circuit in combination with a primary system for plasma collection and a secondary system for controlling.

Technical data

<table>
<thead>
<tr>
<th>Dimension (without filling nozzle)</th>
<th>90.0 x 43.5 mm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adsorber volume</td>
<td>33 ml</td>
</tr>
<tr>
<td>Inlet/Outlet connectors</td>
<td>Luer-Lock</td>
</tr>
<tr>
<td>Ligand</td>
<td>Phosphocholine derivative</td>
</tr>
<tr>
<td>Resin (volume)</td>
<td>Agarose beads (20 ml)</td>
</tr>
<tr>
<td>Max. fluid velocity</td>
<td>100 ml / min</td>
</tr>
<tr>
<td>Max. CRP binding capacity</td>
<td>300 mg</td>
</tr>
<tr>
<td>Max. cumulative treatment time</td>
<td>24 hours</td>
</tr>
<tr>
<td>Max. number of cycles</td>
<td>30</td>
</tr>
<tr>
<td>Storage conditions</td>
<td>2 – 10 °C / 35.6 – 50 °F</td>
</tr>
<tr>
<td>Classification</td>
<td>Medical Device, Class IIb</td>
</tr>
</tbody>
</table>

Literatur


Studies – ongoing and to come

CAMI1  CRP apheresis after myocardial infarction
CAMCRO CRP apheresis in Crohn’s disease
CASTRO CRP apheresis after stroke
CAPR   CRP apheresis in acute pancreatitis
CASIR  CRP apheresis in SIRS (post-op)
CASPAR CRP apheresis in Morbus Bechterew